Bryan Irving
- Immunology top 0.2%
- Immune Cell Function and Interaction 13
- Immunotherapy and Immune Responses 13
- T-cell and B-cell Immunology 12
- Oncology top 0.5%
- CAR-T cell therapy research 18
- Cancer Immunotherapy and Biomarkers 13
- Immunology and Allergy top 1%
-
- Monoclonal and Polyclonal Antibodies Research 23
- Virology top 5%
-
- Glycosylation and Glycoproteins Research 6
-
- Cancer Research and Treatments 3
- Co-authors
- Arthur WeissAndrew C. ChanJames D. FraserJane L. GroganF. Stephen HodiDaniel S. ChenDan EatonXin Yu
- Partner nations
- United StatesFranceSingapore
In The Last Decade
Bryan Irving
44 papers receiving 7.7k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Immunology 5.5k
- Oncology 4.1k
- Immunology and Allergy 366
- Radiology, Nuclear Medicine and Imaging 917
- Virology 162
Countries citing papers authored by Bryan Irving
This map shows the geographic impact of Bryan Irving's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Irving with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Irving more than expected).
Fields of papers citing papers by Bryan Irving
This network shows the impact of papers produced by Bryan Irving. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Irving. The network helps show where Bryan Irving may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bryan Irving, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 35 | |
| 2 | 2020 | 1 | |
| 3 | 2017 | 270 | |
| 4 | MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockadebreakdown → | 2016 | 527 |
| 5 | Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancerbreakdown → | 2015 | 381 |
| 6 | 2015 | 1 | |
| 7 | The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Functionbreakdown → | 2014 | 893 |
| 8 | Pillars article: Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science. 1994. 263: 1136-1139. | 2014 | 2 |
| 9 | 2014 | 232 | |
| 10 | 2013 | 11 | |
| 11 | 2011 | 17 | |
| 12 | The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cellsbreakdown → | 2008 | 1118 |
| 13 | 2000 | 2 | |
| 14 | 1998 | 26 | |
| 15 | 1998 | 153 | |
| 16 | 1994 | 14 | |
| 17 | 1994 | 19 | |
| 18 | 1993 | 289 | |
| 19 | 1992 | 10 | |
| 20 | The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathwaysbreakdown → | 1991 | 703 |
About Bryan Irving
Bryan Irving is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 44 papers that have together received 7.8k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (23 papers), CAR-T cell therapy research (18 papers), Immune Cell Function and Interaction (13 papers), Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (13 papers), T-cell and B-cell Immunology (12 papers), Glycosylation and Glycoproteins Research (6 papers) and Cancer Research and Treatments (3 papers). The work is most often cited by research in Immunology (5.5k citations), Oncology (4.1k citations) and Immunology and Allergy (366 citations). Bryan Irving has collaborated with scholars based in United States, France and Singapore. Frequent co-authors include Arthur Weiss, Andrew C. Chan, James D. Fraser, Jane L. Grogan, F. Stephen Hodi, Daniel S. Chen, Dan Eaton, Xin Yu, Gerald R. Crabtree and Nicolai S. C. van Oers. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Science, Cell and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.